Taken together, our findings reveal that ST6GAL1-mediated aberrant sialylation plays a role in the spread of prostate cancer to bone and suggests upregulation of ST6GAL1 in prostate cancer cells can modulate the pre-metastatic niche by enhancing bone destruction to encourage the outgrowth of incoming prostate cancer cells. Here, ST6GAL1 is linked to prostate cancer.